Exact Mass: 511.1386752000001
Exact Mass Matches: 511.1386752000001
Found 132 metabolites which its exact mass value is equals to given mass value 511.1386752000001
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
3-Methyl-1-hydroxybutyl-ThPP
3-Methyl-1-hydroxybutyl-ThPP is an intermediate in valine, leucine and isoleucine degradation(KEGG ID C15974). It is the second to last step in the synthesis of 3-methylbutanoyl-CoA and is converted from 4-methyl-2-oxopentanoate via the enzyme 2-oxoisovalerate dehydrogenase [EC:1.2.4.4]. It is then converted to S-(3-methylbutanoyl)-dihydrolipoamide-E via the enzyme 2-oxoisovalerate dehydrogenase [EC:1.2.4.4]. [HMDB] 3-Methyl-1-hydroxybutyl-ThPP is an intermediate in valine, leucine and isoleucine degradation(KEGG ID C15974). It is the second to last step in the synthesis of 3-methylbutanoyl-CoA and is converted from 4-methyl-2-oxopentanoate via the enzyme 2-oxoisovalerate dehydrogenase [EC:1.2.4.4]. It is then converted to S-(3-methylbutanoyl)-dihydrolipoamide-E via the enzyme 2-oxoisovalerate dehydrogenase [EC:1.2.4.4].
2-Methyl-1-hydroxybutyl-ThPP
2-Methyl-1-hydroxybutyl-ThPP is an intermediate in Valine, leucine and isoleucine degradation. 2-Methyl-1-hydroxybutyl-ThPP is the second to last step for the synthesis of (S)-2-Methylbutanoyl-CoA. 2-Methyl-1-hydroxybutyl-ThPP is converted from (S)-3-Methyl-2-oxopentanoic acid via the enzyme 2-oxoisovalerate dehydrogenase E1 component, alpha subunit(EC 1.2.4.4). It is then converted to S-(2-Methylbutanoyl)-dihydrolipoamide-E via the same enzyme. 2-Methyl-1-hydroxybutyl-ThPP is an intermediate in Valine, leucine and isoleucine degradation. 2-Methyl-1-hydroxybutyl-ThPP is the second to last step for the synthesis of (S)-2-Methylbutanoyl-CoA. 2-Methyl-1-hydroxybutyl-ThPP is converted
Hygromycin A
C23H29NO12 (511.16896740000004)
A natural product found in Streptomyces species.
Uzel (TN)
C20H21N7O7. Ca (511.11283060000005)
V - Various > V03 - All other therapeutic products > V03A - All other therapeutic products > V03AF - Detoxifying agents for antineoplastic treatment D020011 - Protective Agents > D000931 - Antidotes C2140 - Adjuvant > C2078 - Folic Acid Derivative D018977 - Micronutrients > D014815 - Vitamins Therapeutic category: 3929 Levoleucovorin Calcium (Calcium levofolinate), a levo isoform of Leucovorin Calcium (HY-13664), possesses antineoplastic effects. Levoleucovorin Calcium is also an augmentor of 5-fluorouracil (HY-90006) cytotoxicity against cancer[1][2].
Cefetamet pivoxyl
2-Biphenyl-4-yl-1-(1H-tetrazol-5-yl)ethylaminoethyl phosphonic acid
C28H26N5O3P (511.1773176000001)
Hygromycin A
C23H29NO12 (511.16896740000004)
3-acetyl-3,12-dihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxyhexopyranoside
C27H29NO9 (511.18422240000007)
Cys Cys Met Arg
Cys Cys Arg Met
Cys Cys Thr Trp
Cys Cys Trp Thr
Cys Asp Phe Gln
C21H29N5O8S (511.17367540000004)
Cys Asp Gln Phe
C21H29N5O8S (511.17367540000004)
Cys Glu Phe Asn
C21H29N5O8S (511.17367540000004)
Cys Glu Asn Phe
C21H29N5O8S (511.17367540000004)
Cys Phe Asp Gln
C21H29N5O8S (511.17367540000004)
Cys Phe Glu Asn
C21H29N5O8S (511.17367540000004)
Cys Phe Asn Glu
C21H29N5O8S (511.17367540000004)
Cys Phe Gln Asp
C21H29N5O8S (511.17367540000004)
Cys Met Cys Arg
Cys Met Met Gln
Cys Met Gln Met
Cys Met Arg Cys
Cys Asn Glu Phe
C21H29N5O8S (511.17367540000004)
Cys Asn Phe Glu
C21H29N5O8S (511.17367540000004)
Cys Gln Asp Phe
C21H29N5O8S (511.17367540000004)
Cys Gln Phe Asp
C21H29N5O8S (511.17367540000004)
Cys Gln Met Met
Cys Arg Cys Met
Cys Arg Met Cys
Cys Thr Cys Trp
Cys Thr Trp Cys
Cys Trp Cys Thr
Cys Trp Thr Cys
Asp Cys Phe Gln
C21H29N5O8S (511.17367540000004)
Asp Cys Gln Phe
C21H29N5O8S (511.17367540000004)
Asp Phe Cys Gln
C21H29N5O8S (511.17367540000004)
Asp Phe Gln Cys
C21H29N5O8S (511.17367540000004)
Asp Gln Cys Phe
C21H29N5O8S (511.17367540000004)
Asp Gln Phe Cys
C21H29N5O8S (511.17367540000004)
Glu Cys Phe Asn
C21H29N5O8S (511.17367540000004)
Glu Cys Asn Phe
C21H29N5O8S (511.17367540000004)
Glu Phe Cys Asn
C21H29N5O8S (511.17367540000004)
Glu Phe Asn Cys
C21H29N5O8S (511.17367540000004)
Glu Asn Cys Phe
C21H29N5O8S (511.17367540000004)
Glu Asn Phe Cys
C21H29N5O8S (511.17367540000004)
Phe Cys Asp Gln
C21H29N5O8S (511.17367540000004)
Phe Cys Glu Asn
C21H29N5O8S (511.17367540000004)
Phe Cys Asn Glu
C21H29N5O8S (511.17367540000004)
Phe Cys Gln Asp
C21H29N5O8S (511.17367540000004)
Phe Asp Cys Gln
C21H29N5O8S (511.17367540000004)
Phe Asp Gln Cys
C21H29N5O8S (511.17367540000004)
Phe Glu Cys Asn
C21H29N5O8S (511.17367540000004)
Phe Glu Asn Cys
C21H29N5O8S (511.17367540000004)
Phe Asn Cys Glu
C21H29N5O8S (511.17367540000004)
Phe Asn Glu Cys
C21H29N5O8S (511.17367540000004)
Phe Gln Cys Asp
C21H29N5O8S (511.17367540000004)
Phe Gln Asp Cys
C21H29N5O8S (511.17367540000004)
Met Cys Cys Arg
Met Cys Met Gln
Met Cys Gln Met
Met Cys Arg Cys
Met Met Cys Gln
Met Met Gln Cys
Met Gln Cys Met
Met Gln Met Cys
Met Arg Cys Cys
Asn Cys Glu Phe
C21H29N5O8S (511.17367540000004)
Asn Cys Phe Glu
C21H29N5O8S (511.17367540000004)
Asn Glu Cys Phe
C21H29N5O8S (511.17367540000004)
Asn Glu Phe Cys
C21H29N5O8S (511.17367540000004)
Asn Phe Cys Glu
C21H29N5O8S (511.17367540000004)
Asn Phe Glu Cys
C21H29N5O8S (511.17367540000004)
Gln Cys Asp Phe
C21H29N5O8S (511.17367540000004)
Gln Cys Phe Asp
C21H29N5O8S (511.17367540000004)
Gln Cys Met Met
Gln Asp Cys Phe
C21H29N5O8S (511.17367540000004)
Gln Asp Phe Cys
C21H29N5O8S (511.17367540000004)
Gln Phe Cys Asp
C21H29N5O8S (511.17367540000004)
Gln Phe Asp Cys
C21H29N5O8S (511.17367540000004)
Gln Met Cys Met
Gln Met Met Cys
Arg Cys Cys Met
Arg Cys Met Cys
Arg Met Cys Cys
Thr Cys Cys Trp
Thr Cys Trp Cys
Thr Trp Cys Cys
Trp Cys Cys Thr
Trp Cys Thr Cys
Trp Thr Cys Cys
sodium 3-[[4-(benzoylethylamino)-2-methylphenyl]azo]-4-hydroxynaphthalene-1-sulphonate
C26H22N3NaO5S (511.1177802000001)
Arzoxifene hydrochloride
C28H30ClNO4S (511.1583970000001)
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1821 - Selective Estrogen Receptor Modulator C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C483 - Therapeutic Estrogen C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist C1892 - Chemopreventive Agent
Leucovorin Calcium
V - Various > V03 - All other therapeutic products > V03A - All other therapeutic products > V03AF - Detoxifying agents for antineoplastic treatment D020011 - Protective Agents > D000931 - Antidotes C2140 - Adjuvant > C2078 - Folic Acid Derivative D018977 - Micronutrients > D014815 - Vitamins Levoleucovorin Calcium (Calcium levofolinate), a levo isoform of Leucovorin Calcium (HY-13664), possesses antineoplastic effects. Levoleucovorin Calcium is also an augmentor of 5-fluorouracil (HY-90006) cytotoxicity against cancer[1][2].
[6-acetyloxy-5-(2,5-dioxopyrrol-1-yl)-3-oxospiro[2-benzofuran-1,9-xanthene]-3-yl] acetate
C28H17NO9 (511.09032720000005)
Cefetamet Pivoxil
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D002511 - Cephalosporins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic
(2-Amino-2-biphenylyl)(chloro)palladium - tris(2-methyl-2-propanyl)phosphine (1:1)
C24H37ClNPPd (511.1386752000001)
(E)-CefetametPivoxil
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D002511 - Cephalosporins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams
7,10,13-Tri(carboxymethyl)-5,15-dioxo-4,7,10,13,16-pentaaza-1,19-dithianonadecane
(E)-N-[(3aS,4R,5S,6S,7R,7aR)-4,6,7-trihydroxy-3a,4,5,6,7,7a-hexahydro-1,3-benzodioxol-5-yl]-3-[4-[(2S,3S,4S,5S)-5-acetyl-3,4-dihydroxyoxolan-2-yl]oxy-3-hydroxyphenyl]-2-methylprop-2-enamide
C23H29NO12 (511.16896740000004)
(E)-3-[4-(5-acetyl-3,4-dihydroxyoxolan-2-yl)oxy-3-hydroxyphenyl]-2-methyl-N-(4,6,7-trihydroxy-3a,4,5,6,7,7a-hexahydro-1,3-benzodioxol-5-yl)prop-2-enamide
C23H29NO12 (511.16896740000004)
2-[(3-cyano-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-2-yl)thio]-N-[4-[(3,4-dimethyl-5-isoxazolyl)sulfamoyl]phenyl]acetamide
2,4-Dichloro-benzoic acid 2-{[4-(2,2-dimethyl-propionylamino)-benzoyl]-hydrazonomethyl}-phenyl ester
C26H23Cl2N3O4 (511.10655380000003)
alpha-Kdo1Me-(2->8)-alpha-Kdo-OAll(1-)
C20H31O15- (511.16628760000003)
CGP71683 hydrochloride
C26H30ClN5O2S (511.18086300000004)
CGP71683 hydrochloride is a competitive neuropeptide Y5 receptor antagonist with a Ki of 1.3 nM, and shows no obvious activity at Y1 receptor (Ki, >4000 nM) and Y2 receptor (Ki, 200 nM) in cell membranes.
CVT-11127
CVT-11127 is a potent SCD inhibitor. CVT-11127 induces apoposis and arrests the cell cycle at the G1/S phase. CVT-11127 has the potential for the research of lung cancer[1]. CVT-11127 is a potent SCD inhibitor. CVT-11127 induces apoposis and arrests the cell cycle at the G1/S phase. CVT-11127 has the potential for the research of lung cancer[1].
PPTN (hydrochloride)
PPTN hydrochloride is a potent, high-affinity, competitive and highly selective P2Y14 receptor antagonist with a KB value of 434 pM. PPTN hydrochloride exhibits no agonist or antagonist effect at the P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, or P2Y13 receptors. Anti-inflammatory and anti-immune activity[1].
(2e)-n-[(3ar,4s,5s,6r,7s,7as)-4,6,7-trihydroxy-hexahydro-2h-1,3-benzodioxol-5-yl]-3-(4-{[(2s,3s,4s,5s)-5-acetyl-3,4-dihydroxyoxolan-2-yl]oxy}-3-hydroxyphenyl)-2-methylprop-2-enimidic acid
C23H29NO12 (511.16896740000004)
(1s,11s,13s,14r,15s,16s)-15-hydroxy-14-methoxy-5,7,21-trioxa-20-azahexacyclo[11.4.3.1¹¹,¹⁴.0¹,¹³.0²,¹⁰.0⁴,⁸]henicosa-2,4(8),9-trien-16-yl 3,4-dimethoxybenzoate
C27H29NO9 (511.18422240000007)
(5s,7r,8s,9r,10r,18r)-18-ethyl-9,10-dihydroxy-8-methoxy-7,23-dimethyl-4,6,19-trioxa-22-azahexacyclo[12.11.0.0³,¹¹.0⁵,¹⁰.0¹⁶,²⁵.0¹⁷,²²]pentacosa-1(25),3(11),13,16,23-pentaene-2,12,15,20-tetrone
(2e)-3-(4-{[(2s,3s,4s,5s)-5-acetyl-3,4-dihydroxyoxolan-2-yl]oxy}-3-hydroxyphenyl)-2-methyl-n-[(4r,5r,6s,7r)-4,6,7-trihydroxy-hexahydro-2h-1,3-benzodioxol-5-yl]prop-2-enimidic acid
C23H29NO12 (511.16896740000004)
1-[5-({[2-amino-1,4-dihydroxy-4-(5-hydroxypyridin-2-yl)-3-methylbutylidene]amino}(carboxy)methyl)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyimidazole-4-carboxylic acid
C20H25N5O11 (511.15504999999996)